Medpace (NASDAQ:MEDP) updated its FY18 earnings guidance on Monday. The company provided earnings per share guidance of $1.82 to $1.93 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.80. The company issued revenue guidance of $412 million to $428 million, compared to the consensus revenue estimate of $423.58 million.
Several analysts have recently commented on the company. Credit Suisse Group restated an outperform rating and issued a $42.00 target price (up from $41.00) on shares of Medpace in a research note on Tuesday, February 27th. BidaskClub upgraded Medpace from a hold rating to a buy rating in a research note on Thursday, December 14th. Jefferies Group reaffirmed a hold rating and issued a $35.00 price target on shares of Medpace in a research report on Thursday, March 1st. Wells Fargo & Co dropped their price target on shares of Medpace from $38.00 to $35.00 and set a market perform rating on the stock in a research report on Wednesday, February 28th. Finally, Zacks Investment Research raised shares of Medpace from a hold rating to a buy rating and set a $40.00 price target on the stock in a research report on Wednesday, December 13th. Seven equities research analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has a consensus rating of Hold and a consensus target price of $36.83.
Shares of Medpace (NASDAQ:MEDP) traded down $0.14 during midday trading on Wednesday, reaching $33.65. 3,682 shares of the company traded hands, compared to its average volume of 219,775. Medpace has a twelve month low of $21.76 and a twelve month high of $39.64. The company has a market cap of $1,190.87, a PE ratio of 22.23, a price-to-earnings-growth ratio of 1.38 and a beta of 0.50. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.67 and a current ratio of 0.67.
Medpace (NASDAQ:MEDP) last posted its earnings results on Monday, February 26th. The company reported $0.39 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.38 by $0.01. Medpace had a net margin of 8.97% and a return on equity of 10.55%. The firm had revenue of $99.45 million for the quarter, compared to analysts’ expectations of $97.25 million. During the same quarter last year, the firm earned $0.35 EPS. The company’s quarterly revenue was up 4.3% compared to the same quarter last year. equities analysts predict that Medpace will post 1.88 EPS for the current fiscal year.
Medpace Company Profile
Medpace Holdings, Inc is a clinical contract research organization. The Company provides clinical research-based drug and medical device development services. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support.